Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Fresh Approaches to RT Improve Outcomes in Retroperitoneal Sarcoma

July 15th 2019

Each year, 10% to 15% of patients with soft-tissue carcinomas receive a diagnosis of rare retroperitoneal sarcoma (RPS), an aggressive disease that typically recurs in 26% of cases and has a 47% to 67% five-year overall survival rate. New radiation therapies hold potential to decrease treatment time and provide local control of RPS.

Investigators Express Confidence in a Novel TKI That Targets Rare Sarcomas

June 26th 2019

Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes where patients have limited therapeutic options.

FDA Approval Sought for Tazemetostat for Epithelioid Sarcoma

May 30th 2019

A new drug application has been submitted to the FDA for tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

Dr. Navai on Treatment Options in Relapsed/Refractory Sarcoma

May 17th 2019

Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.

FDA Panel Backs Pexidartinib for Tenosynovial Giant Cell Tumor

May 14th 2019

The FDA’s Oncologic Drugs Advisory Committee voted in favor of pexidartinib for an indication as a treatment of adult patients with symptomatic tenosynovial giant cell tumor.

FDA Grants Pomalidomide Breakthrough Designation in Kaposi Sarcoma

May 13th 2019

The FDA has granted a breakthrough therapy designation to pomalidomide for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative Kaposi sarcoma.

Dr. Schlumbrecht on Investigational Treatment Strategies in Uterine Leiomyosarcoma

May 9th 2019

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational treatment strategies in uterine leiomyosarcoma.

EU Panel Recommends Revoking Olaratumab in Soft Tissue Sarcoma

April 29th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that the conditional marketing authorization for olaratumab be revoked following results of the ANNOUNCE study, which did not demonstrate a survival benefit with the PDGFRα antagonist in combination with doxorubicin versus doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma.

Olaratumab to Be Withdrawn From Market, Access Program Planned in Soft Tissue Sarcoma

April 26th 2019

Eli Lilly and Company has announced that it is withdrawing its PDGFRα antagonist olaratumab from the market for the treatment of patients with advanced soft tissue sarcoma.

FDA Schedules ODAC Meetings for Pexidartinib in TGCT and Quizartinib in AML

April 19th 2019

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for May 14, 2019, to discuss a new drug application for pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor.

Dr. George on the Importance of Collaboration in the Treatment of Uterine Sarcomas

April 4th 2019

Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of medicine, Harvard Medical School, discusses the importance of collaboration in the treatment of patients with uterine sarcoma.

LOXO-195 Active After Initial Anti-TRK Failure in Multiple Tumor Types

April 2nd 2019

A third of patients with advanced TRK fusion tumors had objective responses to the second-generation TRK inhibitor LOXO-195 after failure of initial anti-TRK therapy.

When a Measure of Significance Is Not All That Significant

March 20th 2019

The term statistically significant is almost certainly beautiful music to the ears of clinical investigators and pharma/biotech companies. However, concern develops when one inquires how the most common test of significance, the P value, is used in clinical investigative efforts and whether at times this is more harmful than helpful within the domain of cancer medicine.

Dr. Ganjoo on the Treatment of Metastatic Uterine Leiomyosarcoma

February 21st 2019

Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the treatment of patients with metastatic uterine leiomyosarcoma.

Dr. George Discusses Ongoing Trials in Soft Tissue Sarcoma

February 12th 2019

Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of Medicine, Harvard Medical School, discusses ongoing trials in soft tissue sarcoma (STS).

FDA Grants Priority Review to Pexidartinib for Tenosynovial Giant Cell Tumor

February 6th 2019

The FDA has granted a priority review designation to a new drug application for the investigational, small molecule, CSF1R receptor inhibitor pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor.

FDA, EMA Recommend Against Starting Olaratumab for Soft Tissue Sarcoma

January 25th 2019

The FDA and European Medicines Agency have recommended that no new patients with advanced soft tissue sarcoma should be treated with the combination of olaratumab plus doxorubicin.

Olaratumab Falls Short in Phase III Soft Tissue Sarcoma Trial

January 18th 2019

Olaratumab in combination with doxorubicin missed the phase III ANNOUNCE trial’s primary endpoint of overall survival and did not confirm a clinical benefit for patients with advanced or metastatic soft tissue sarcoma compared with standard doxorubicin.

FDA Issues Letter Regarding Safety Concerns With Paclitaxel-Coated Devices

January 18th 2019

The FDA has issued a letter to healthcare providers that they should monitor patients with a type of peripheral arterial disease who have been treated with vascular balloons that were coated with paclitaxel or stents that release paclitaxel in the femoropopliteal artery in the leg.

Novel Strategies Emerging in Uterine Sarcomas

January 17th 2019

Suzanne George, MD, highlights the available therapies for patients with uterine sarcomas and what novel options are on the horizon.